Heart failure

PREDICTION AND PREVENTION OF SUDDEN CARDIAC DEATH IN HEART FAILURE

Rebecca E Lane, Martin R Cowie, Anthony W C Chow


The definition of sudden cardiac death (SCD) remains controversial. Many such deaths are not witnessed, and without cardiac monitoring at the time of death the assumption of an underlying arrhythmic cause is speculative. Nevertheless, it has been estimated that SCD accounts for 300 000 to 400 000 deaths annually in the USA.1 The degeneration of monomorphic ventricular tachycardia (VT) into ventricular fibrillation (VF) accounts for the majority of sudden arrhythmic deaths.2

Despite considerable advances in the treatment of heart failure over the past 20 years, morbidity and mortality remain high with a four year survival of less than 50% in population based studies (fig 1). Ventricular arrhythmias (including non-sustained VT) have been documented in up to 85% of patients with severe congestive heart failure.3

The implantable cardioverter-defibrillator (ICD) is highly effective at terminating life threatening ventricular tachyarrhythmia (fig 2). In selected high risk patients ICDs have proven to be a cost effective method of reducing mortality. At present, 1–2% of the population has heart failure and numbers continue to increase,3 but the ICD remains expensive. The challenge lies in identifying patients with heart failure who are at significant risk of arrhythmia and who would benefit from an ICD in addition to other antiarrhythmic strategies.

RISK STRATIFICATION OF SCD

Heart failure aetiology

Patients with heart failure caused by ischaemic heart disease are generally considered to be at high risk of SCD, and have been the focus of many large randomised controlled trials of primary and secondary prevention of SCD. In the second multicenter automatic defibrillator implantation trial (MADIT II)4 of patients with low left ventricular ejection fraction (LVEF) and previous myocardial infarction, the all cause mortality was around 10% per year. In the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) of patients with symptomatic heart failure and LVEF < 40%, the one year mortality in the placebo arm was 13.6%, despite optimal medical therapy. The 12 month SCD rate was almost 5% increasing to nearly 8% at two years.5

The annual mortality in dilated cardiomyopathy (DCM) has been reported to range from 10–50% from referral centres, with up to 28% of deaths being classified as sudden.6,7 More recent studies of DCM patients on optimal medical treatment have reported considerably lower mortality rates of around 7% at two years.7 Although patients with DCM were excluded from many early ICD studies, a number of recent randomised trials have included such patients and will provide crucial outcome data to guide patient management.6

The recently reported sudden cardiac death in heart failure trial (SCD-HeFT) demonstrated similar relative risk reductions in mortality in ischaemic and non-ischaemic patients (21% and 27%, respectively) suggesting that the use of ICDs in patients with severely depressed left ventricular (LV) function was beneficial regardless of the aetiology of heart failure.9 The results were less conclusive in the cardiomyopathy trial (CAT) of patients with DCM: the study was terminated early with no reduction in all cause mortality at two and four years follow up, although the study was underpowered.7

New York Heart Association class

Mortality rates increase the higher the New York Heart Association (NYHA) class, but the proportion of patients dying suddenly (rather than from progressive pump failure) is highest among those with less severe heart failure (NYHA class II or III) (fig 3).6,7 Many of the randomised controlled trials have excluded patients in NYHA class IV, making decisions for use of therapeutic strategies for SCD more difficult in those patients with the worst prognosis.

Syncope

Syncope is an important risk factor for SCD in patients with advanced heart failure, regardless of the underlying aetiology.3,9 Observational data suggest that around 30% of patients with DCM, NYHA
class III or IV symptoms, and recurrent syncope, will receive an appropriate shock for ventricular arrhythmia by one year after implantation of an ICD, rising to around 50% by two years.\textsuperscript{w4 w5}

**Left ventricular systolic dysfunction**

Patients with severe LV systolic dysfunction are among those at greatest risk for SCD. However, it remains uncertain whether the degree of LV impairment per se can be used to estimate the risk of SCD. During four years of follow up after implantation of an ICD in patients with documented ventricular arrhythmia, both the proportion of patients who had received an ICD therapy and the sudden death rates were comparable between patients with moderate or severe LV dysfunction (LVEF $\leq 30\%$ and $\geq 30\%$, respectively).\textsuperscript{w6}

**QRS duration**

In patients with documented ventricular arrhythmias and moderately severe heart failure caused by poor LV systolic function, a long QRS duration was associated with a higher risk of death from a cardiac cause.\textsuperscript{w7} Intraventricular conduction delay is used in the heart failure survival score for estimating prognosis in patients with severe heart failure.\textsuperscript{w8} The QRS duration has not been used as an inclusion criterion in randomised controlled ICD trials, although there is some evidence from post hoc subgroup analysis that the benefit of ICD therapy may be greater in those with broader QRS complexes.

**QT dispersion**
The dispersion of the QT interval on the surface ECG is increased in patients with heart failure. This was initially considered to be associated with an increased risk of
ventricular arrhythmias and SCD, but this finding has proved inconsistent.

Holter monitoring
Before hospital discharge after acute myocardial infarction, around 9% of patients will have non-sustained VT on Holter monitoring. Only a minority of such patients also have a low LVEF. The presence of non-sustained VT has a very low positive predictive value for subsequent arrhythmic events or mortality in this clinical setting.

In patients with chronic heart failure, however, the presence of non-sustained VT has been shown to identify a population at high risk of SCD. Patients with DCM (LVEF < 30%) and a history of non-sustained VT have an incidence of appropriate ICD interventions similar to that of DCM patients with a history of syncope or sustained VT/VF, at around 37% over three years.

In the defibrillator in non-ischaemic cardiomyopathy treatment evaluation (DEFINITE) trial, in patients with DCM (LVEF < 36%) on optimal medical treatment with premature ventricular complexes or non-sustained VT, the ICD significantly reduced the risk of the primary end point of SCD by 80% (95% confidence interval (CI) 29% to 94%), with a non-significant reduction in the risk of death from any cause.

Signal averaged ECG
The signal averaged ECG (SAECG) is a highly amplified, processed ECG that detects microvolt electrical potentials (late potentials) in the terminal QRS complex originating from abnormal scarred myocardium with regions of slow conduction. The presence of late potentials on SAECG has been shown to identify patients at high arrhythmic risk after myocardial infarction.

In the multicenter unsustained tachycardia trial (MUSTT), an abnormal SAECG combined with an LVEF < 30% in patients with coronary artery disease was found to predict those patients at highest risk of arrhythmic and cardiac death.

In contrast, no mortality difference was demonstrated between those with LV systolic dysfunction and an abnormal SAECG randomised to either ICD or to the control group at the time of coronary artery bypass surgery in the coronary artery bypass graft (CABG) Patch trial.

There is no evidence that SAECG is of value in risk stratification of patients with DCM, as this has been found to have both a low sensitivity and specificity for serious arrhythmic events.

As a screening test the SAECG has a number of limitations. Late potentials from the anteroseptal walls may be masked within the main QRS because these areas are activated earliest. Similarly, late potentials may not outlast an abnormally wide QRS, and may not be detected even in patients with inducible VT.

Heart rate variability and baroreflex sensitivity
Abnormalities of the autonomic nervous system have been implicated in the genesis of SCD in patients with heart failure after myocardial infarction. Specific autonomic parameters (such as heart rate variability) reflect neurohormonal interaction with the sinus node and are decreased by the raised sympathetic activity observed in heart failure. In the multicentre postinfarction study a strong correlation was found between reduced heart rate variability and all cause mortality after acute myocardial infarction, with greatest prognostic value in those patients with an LVEF < 30%. However, the changes observed acutely were transient and almost completely vanished within 6–12 weeks. The value of this test is, of course, significantly limited in patients with atrial fibrillation or frequent premature atrial or ventricular complexes.

T wave alternans
Beat-to-beat variation in T wave amplitude known as microvolt T wave alternans (TWA) may be a useful tool for risk stratifying SCD in heart failure, regardless of the aetiology of heart failure, but has yet to be fully evaluated. Early reports suggest a very high negative predictive value, combined with an arrhythmogenic event rate (SCD, cardiac arrest, or sustained VT) of around 15–20% over 1–2 years follow up in those with positive or indeterminate TWA.

Electrophysiologic testing
Two randomised trials of primary prevention of SCD, the first multicenter automatic defibrillator implantation trial (MADIT) and MUSTT, required sustained ventricular tachyarrhythmia to be inducible at formal electrophysiological (EP) testing in patients with coronary artery disease, asymptomatic non-sustained VT, and impaired LV systolic function, before randomisation to prophylactic ICD or conventional anti-arrhythmic drug treatment. Both demonstrated a > 50% relative risk reduction in all cause mortality.

However, the lack of inducible sustained ventricular tachyarrhythmia at EP testing in the MUSTT study did not exclude the risk of cardiac arrest or arrhythmic death even within two years (negative predictive value was only 88%). In such patients, the absolute risk of SCD remains high (12% at two years, 24% at five years) with an overall mortality rate of 44% at five years with 45% of deaths reported to result from arrhythmia.

EP testing may fail to provoke tachycardia altogether in DCM and should not be relied upon to exclude the risk of SCD.

The induction of sustained monomorphic VT at EP testing therefore provides clear identification of patients at high risk of SCD for whom primary prevention with an ICD is advised. Failure to induce VT does not equate to no risk and thus poses important clinical management problems.

B-type natriuretic peptide
B-type natriuretic peptide (BNP) is secreted primarily from the left ventricle in response to changes in myocardial wall stretch. The plasma concentration of this peptide is strongly correlated with the degree of LV dysfunction and the risk of death. In a study of 452 patients with ischaemic or non-ischaemic cardiomyopathy and LVEF < 35%, a plasma BNP cut off point of 130 pg/ml gave a 99% negative predictive value for SCD, with a positive predictive value of only 19% over an average 18 month follow up. This requires prospective validation.

PREVENTION OF SCD
Pharmacotherapy
Angiotensin converting enzyme inhibitors
Angiotensin converting enzyme (ACE) inhibitors reduce total mortality in patients with systolic heart failure recruited to randomised placebo controlled trials, and are considered first line agents. The mortality benefit is seen in all NYHA classes, but was seen with greatest absolute benefit among those with the most severely impaired LV function. ACE inhibitors have been shown to decrease death from progressive heart...
<table>
<thead>
<tr>
<th>Name of trial</th>
<th>Heart failure aetiology and severity</th>
<th>Number of patients</th>
<th>Additional risk stratification tool</th>
<th>Treatment groups</th>
<th>Primary and *secondary outcomes</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVID*</td>
<td>Mean LVEF 32%</td>
<td>1016</td>
<td>Resuscitated VF or VT</td>
<td>1. Class III antiarrhythmic drugs</td>
<td>1. Total mortality</td>
<td>1.39% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>*2. QOL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*3. Cost</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>1. Total mortality</td>
<td>1.20% relative risk reduction (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*2. Arrhythmic death</td>
<td>2.33% relative risk reduction (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Total mortality</td>
<td>1.54% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>1. Cardiac arrest or death</td>
<td>1.27% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>from arrhythmia</td>
<td>*2. Total mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*3. Sustained VT</td>
<td>3. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Amiodarone x placebo: No reduction</td>
<td>ICD x placebo: 23% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Amiodarone</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Antiarrhythmic treatment</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. No antiarrhythmic treatment</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>1. Cardiac arrest or death</td>
<td>1.31% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>from arrhythmia</td>
<td>*2. Total mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*3. Sustained VT</td>
<td>3. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Medical treatment</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Medical treatment</td>
<td>1. Amiodarone x placebo: No reduction</td>
<td>ICD x placebo: 23% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Medical treatment</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Medical treatment</td>
<td>1. Amiodarone</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Placebo</td>
<td>2. Antiarrhythmic treatment</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Placebo</td>
<td>2. No antiarrhythmic treatment</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. ICD</td>
<td>1. Cardiac arrest or death</td>
<td>1.31% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. ICD</td>
<td>from arrhythmia</td>
<td>*2. Total mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. ICD</td>
<td>*3. Sustained VT</td>
<td>3. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. ICD</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td>CABG surgery, LVEF &lt;36%</td>
<td>900</td>
<td>Abnormal SAECG</td>
<td>1. ICD</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td>Prior MI, LVEF &lt;30%</td>
<td>1232</td>
<td>None</td>
<td>2. Control</td>
<td>2. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td>IHD or DCM, NYHA II–III, LVEF &lt;35%</td>
<td>&gt;2500</td>
<td>None</td>
<td>2. ICD</td>
<td>1. Medical treatment</td>
<td>1. Total mortality</td>
</tr>
<tr>
<td></td>
<td>DCM, NYHA I–III, LVEF &lt;35%</td>
<td>103</td>
<td>Asymptomatic NSVT</td>
<td>1. Amiodarone</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>*2. Arrhythmic-free survival</td>
<td>2. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*3. QOL</td>
<td>3. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*4. Cost</td>
<td>4. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td>DCM, LVEF &lt;36%</td>
<td>458</td>
<td>PVCs or NSVT</td>
<td>1. Control</td>
<td>1. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. ICD</td>
<td>2. Total mortality</td>
<td>1. NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Medical treatment + ICD</td>
<td>1. Total mortality</td>
<td>1.35% relative risk reduction (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Antiarrhythmic death</td>
<td>*2. Death or hospitalisation from heart failure</td>
<td>2.40% relative risk reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. CRT</td>
<td>1.35% relative risk reduction</td>
<td>*3. Total mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. CRT with ICD</td>
<td>1.35% relative risk reduction</td>
<td>*3. Total mortality</td>
</tr>
</tbody>
</table>

CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; DCM, idiopathic dilated cardiomyopathy; EPS, electrophysiological study; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, non-significant; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; PVC, premature ventricular complex; QOL, quality of life; SAECG, signal averaged ECG; VF, ventricular fibrillation; VT, ventricular tachycardia.
failure, but a recent meta-analysis did not report a consistent effect on arrhythmic mortality.\textsuperscript{21}

\textbf{Aldosterone receptor antagonists}

A 30% reduction in mortality was achieved by the use of spironolactone in addition to an ACE inhibitor and diuretic in patients with moderate to severe heart failure caused by LV systolic dysfunction (NYHA class III or IV).\textsuperscript{22} This mortality benefit was attributed to a lower risk of death caused by both progressive heart failure and SCD. The postulated mechanisms for reducing SCD included increased serum potassium, increased myocardial uptake of noradrenaline (norepinephrine), and decreased myocardial fibrosis. In the recently reported EPESUS trial of heart failure or LV systolic dysfunction after acute myocardial infarction, the aldosterone receptor antagonist eplerenone significantly reduced overall mortality by 15%, and SCD by 21%.\textsuperscript{23} In the subgroup of patients with an LVEF < 30%, eplerenone reduced SCD by 33%.\textsuperscript{24,20}

\textbf{β Blockers}

β Blockers have been shown to reduce morbidity and mortality in patients with chronic heart failure in randomised controlled trials, and consistently reduce the risk of SCD by between 40–55%.\textsuperscript{25–27} The use of carvedilol (in addition to ACE inhibitors) in the carvedilol post-infarct survival control in LV dysfunction (CAPRICORN) study of patients after myocardial infarction with LVEF < 40%, produced a significant reduction in total mortality, and a trend toward fewer SCD.\textsuperscript{28,29}

\textbf{Antiarrhythmic agents}

Clinical trials using class I antiarrhythmic drugs to suppress ventricular arrhythmia in patients after acute myocardial infarction were terminated prematurely because of an excess mortality attributed to drug induced pro-arrhythmia.\textsuperscript{30,31} Two large randomised studies have specifically assessed amiodarone treatment as a primary prevention strategy for SCD in heart failure, with variable results. The GESICA (gruppo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina) trial reported a 28% risk reduction in mortality among NYHA III–IV patients randomised to treatment with amiodarone, compared with placebo. However, reductions in SCD were not significant.\textsuperscript{32} In contrast, the survival trial of antiarrhythmic therapy for congestive heart failure (CHF-STAT) (LVEF < 40% and > 10 ventricular ectopics per hour) found no reduction in SCD or mortality benefit from treatment with amiodarone, although there was a strong trend to mortality benefit in those with a non-ischaemic aetiology.\textsuperscript{33} Similarly, the recently completed SCD-HeFT study reported no survival benefit from the use of amiodarone in patients with either ischaemic or non-ischaemic cardiomyopathy in comparison with placebo.\textsuperscript{34}

Even among patients presenting with symptomatic ventricular arrhythmias, the efficacy of antiarrhythmic drug treatment is disappointing. At best, half of patients treated for VT are rendered non-inducible at EP study, and there is a high recurrence rate of clinical arrhythmia.\textsuperscript{35} A careful risk–benefit evaluation is recommended before prescribing antiarrhythmic drugs for patients with significant LV systolic dysfunction.

\textbf{Device therapy}

\textbf{Implantable cardioverter-defibrillator}

A number of trials have established the efficacy of ICDs in reducing mortality by 20–60% (compared with antiarrhythmic drug treatment) over a 2–5 year follow up period in patients with poor LV function and documented (or inducible) ventricular arrhythmia.\textsuperscript{36,37} Trials have also been conducted in the primary prevention of SCD using the ICD in patients with LV systolic dysfunction without documented arrhythmia. All cause mortality was reduced by 31% over two years (p = 0.016) in the MADIT II study of patients with low LVEF and previous myocardial infarction, and 23% over five years (p = 0.007) in the SCD-HeFT study of patients with low LVEF, NYHA class II or III, and either ischaemic or non-ischaemic cardiomyopathy (table 1).\textsuperscript{38} The mortality in the optimal medical treatment arms of both of these trials was around 7–10% per year.

\textbf{Biventricular pacing}

In patients with advanced LV systolic dysfunction, concomitant conduction tissue disease may contribute to worsening heart failure because of loss of ventricular synchrony. Right ventricular pacing may induce ventricular dyssynchrony iatrogenically and worsen heart failure.\textsuperscript{39–41} Biventricular pacing attempts to resynchronise the failing heart providing functional and symptomatic improvements,\textsuperscript{42} and is
Increasingly used in combination with an ICD (fig 4). Preliminary data from the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) study found biventricular pacing to reduce all cause mortality by 24% \((p = 0.06)\) compared to optimal medical treatment at 12 months, the benefit increasing to 36% \((p = 0.003)\) with a combined biventricular pacemaker-defibrillator. It seems likely that the use of combined devices will continue to expand with significant cost implications.

**Guidelines**

Following the publication of MADIT II and CAT, the European Society of Cardiology guidelines on primary prevention of SCD were updated.\(^2\) Secondary prevention of SCD with an ICD remained the strongest possible recommended (class I) indication for patients with LV systolic dysfunction and heart failure—whether ischaemic or non-ischaemic.

In patients with heart failure after acute myocardial infarction, \(\beta\) blockers, ACE inhibitors, and aldosterone receptor blockers were recommended with class I indication. Amiodarone and the implantation of an ICD in patients with an LVEF < 30% were both given a class IIa indication (“some controversy but weight of evidence in favour”). Although the use of the ICD in primary prevention has been shown to reduce mortality,\(^3\) it was agreed that concordant results from other studies would be required before a class I recommendation could be given.\(^4\)

For DCM, ACE inhibitors and \(\beta\) blockers were given class I indications for both primary and secondary prevention of SCD, and aldosterone receptor antagonists class IIa indication. Patients with symptomatic DCM (NYHA class II–III), LVEF < 30%, without documented symptomatic ventricular tachyarrhythmia (as in the CAT study) do not have a very poor short term prognosis with consequent downgrading of the indication for an ICD from class IIa to IIb (“efficacy less well established”).\(^5\)

Since this update several trials of SCD prevention have been published. A joint American Heart Association/American College of Cardiology/European Society of Cardiology guideline is due to be published shortly.

**CONCLUSION**

The number of patients with heart failure at risk of SCD is increasing. No single test reliably predicts arrhythmic risk in patients with heart failure—a combination of tests improves risk stratification and helps identify patients at greatest risk of SCD. A

---

**Figure 5** Algorithm for the assessment and management of patients with heart failure at risk of sudden cardiac death. ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; BNP, B type natriuretic peptide; BP, blood pressure; CRT, cardiac resynchronisation therapy; EPS, electrophysiological study; HRV, heart rate variability; ICD, implantable cardioverter-defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; SAECG, signal averaged ECG; SCD, sudden cardiac death; TWA, T wave alternans; VT, ventricular fibrillation; VF, ventricular tachycardia.
All heart failure patients should have their medical treatment optimised—the use of ACE inhibitors, β blockers, and aldosterone blockers are likely to improve prognosis, and reduce the risk of SCD. The ICD offers an effective therapy for treating malignant ventricular arrhythmia and is indicated for the secondary prevention of SCD. Primary prevention strategies are being refined, and the result of recent clinical trials along with discussions regarding the cost effectiveness of different strategies will consolidate the professional consensus in the coming years. More, rather than less, implants are likely to be needed.

Additional references appear on the Heart website—http://www.heartjnl.com/supplemental

References

5. MADIT II was a randomised controlled trial of implantable defibrillator versus medical treatment. Prophylactic implantation of a defibrillator in patients with reduced left ventricular ejection fraction and prior myocardial infarction significantly reduced mortality.
7. Aldosterone blockade with eplerenone reduces morbidity and mortality among patients with acute myocardial infarction and left ventricular dysfunction with a 21% reduction in sudden cardiac death.
11. This randomised controlled trial failed to demonstrate a reduction in mortality with prophylactic ICD implantation in patients with DCM and impaired ejection fraction.
13. Multicentre randomised controlled trial of >1500 patients randomised to receive optimal pharmacologic treatment alone or in combination with cardiac resynchronisation therapy with or without a pacemaker and pacemaker-defibrillator, CRT with an ICD significantly reduced mortality.

This randomised controlled trial found the implantation of a defibrillator significantly reduced the risk of sudden death from arrhythmia in patients with severe, non-ischemic dilated cardiomyopathy treated with ACE inhibitors and β blockers.

In this study an abnormal SAECG predicted arrhythmic death or cardiac arrest in 56% of patients with coronary artery disease, un sustained VT, and LV dysfunction.


This large multicentre trial showed a negative electrophysiologic study in patients with coronary artery disease, left ventricular dysfunction and non-sustained ventricular tachycardia was associated with a significantly lower risk of sudden death.


In this multicentre trial of >2600 patients with symptomatic heart failure in NYHA III or IV, the addition of bisoprolol to standard optimal medical treatment significantly reduced all cause mortality and sudden cardiac death.


This randomised controlled trial demonstrated a reduction in all cause mortality in patients with heart failure treated with amiodarone.


This study found amiodarone failed to reduce the incidence of sudden death or prolong survival among patients with heart failure and LV ejection fraction <40%.


This paper outlines recent updates to ESC guidelines on sudden cardiac death incorporating data from MADIT II and CAT. Further recommendations will follow with the publication of additional important trials of the prevention sudden cardiac death.


Additional references appear on the Heart website—http://www.heartjnl.com/supplemental

www.heartjnl.com